O besity is upstream the metabolic syndrome, which is a cluster of type 2 diabetes, hypertension, and dyslipidemia. 1 Recent progresses in adipocyte biology have partly clarified molecular mechanism of metabolic syndrome, but its mechanism has not been fully understood. 2 We reported previously that adiponectin is abundantly expressed in adipose tissue and is secreted from adipocytes into the circulation. Interestingly, plasma adiponectin levels correlate inversely with body mass index, although adiponectin mRNA is expressed specifically in adipocytes. A number of clinical trials showed that hypoadiponectinemic subjects are liable to type 2 diabetes and myocardial infarction. We and other groups analyzed mice lacking or overexpressing adiponectin and reported that adiponectin exhibits antidiabetic, antiatherosclerotic, and antiinflammatory effects. Thus, adiponectin may be a protective molecule in the development of metabolic syndrome. 3 The renin-angiotensin-aldosterone system (RAAS) is often activated in human subjects and animal models with metabolic syndrome as well as heart failure. 4 Accumulating evidence has shown that RAAS exists not only in the circulation where it is driven by renal renin, but it is activated locally also in many tissues and cells. In this context, the use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) has been recognized as an important element in clinical therapeutic strategy not only for hypertension but also for diabetes, heart failure, and cardiovascular diseases, suggesting that blockade of activated RAAS may be a significant therapeutic target for metabolic syndrome as well as heart failure. Angiotensin II (Ang II) is produced by the enzymatic cascade involved in RAAS and strongly causes cell proliferation and migration, and vascular contraction. Another important effect of Ang II is the induction of intracellular oxidative stress and promotion of tissue fibrosis. 5, 6 Thus, Ang II may contribute to the pathogenesis of heart failure and metabolic syndrome.
Recently, several clinical reports have shown the increased frequency of left ventricular (LV) dysfunction and structural abnormalities in subjects with metabolic syndrome. 7, 8 Studies in animal models of metabolic syndrome have also demonstrated the presence of cardiac fibrosis in such animals compared with the control. 9, 10 However, the molecular mechanism(s) that links fibrosis and metabolic syndrome has not been elucidated.
Based on the above background, we hypothesized the molecular association of adiponectin and Ang II in the pathogenesis of cardiac fibrosis. To test our hypothesis, we investigated the functional role of adiponectin in Ang II-induced cardiac fibrosis by using mice and cultured cardiac fibroblasts.
Methods
Adiponectin knockout (Adipo-KO) mice were generated and backcrossed to C57BL/6J over 6 generations as described previously. 11 PPAR-␣ knockout (PPAR-␣-KO) mice were purchased from the Jackson Laboratory (Bar Harbor, Me). The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Osaka University School of Medicine. Details of in vivo and in vitro experiments are fully described in supplemental Methods, available online at http://atvb.ahajournals.org.
Results

Severe Ang II-Induced Cardiac Fibrosis in Adiponectin-Deficient Mice
We treated with Ang II to wild-type (WT) and Adipo-KO mice at various infusion rates (0 to 1.2 mg/kg/d) those were not deviated from previous experiments. [12] [13] [14] Ang II increased systolic blood pressures (sBP), although there was no significant difference in sBP between WT and Adipo-KO mice at each dose of Ang II (supplemental Figure I-a) . The heart weight/body weight (HW/BW) ratio was significantly higher in Adipo-KO mice than WT mice at 1. 
Expression of Molecules Related to Ang II-Induced Cardiac Fibrosis
We measured mRNA levels relating to cardiac fibrosis. Collagen I and III and transforming growth factor (TGF)-␤1 were significantly higher in Adipo-KO mice than in WT mice at Ang II infusion rate of 1.2 mg/kg/d (supplemental Figure  II-a to II-c) . The mRNA ratio of ␤-myosin heavy chain (MHC) to ␣-MHC, a marker of cardiac hypertrophy, did not change in both mice at the same dose of Ang II (supplemental Figure II-d) . Activation of NADPH oxidase is located upstream of ROS production and is a major player in Ang II-induced fibrosis. 5, 6 Administration of Ang II at 1.2 mg/ kg/d resulted in significantly higher elevations of p22 phox and p47 phox mRNA levels in Adipo-KO mice relative to those of WT mice (supplemental Figure II Peroxisome proliferator-activated receptor (PPAR) ␣ is considered to be located downstream of adiponectin. 15 Thus, to examine whether adiponectin operates on cardiac fibrosis through PPAR-␣, we injected adenovirus-producing adiponectin (Ad-Adipo) to WT, Adipo-KO, and PPAR-␣ knockout (PPAR-␣-KO) mice administered with Ang II at 1.2 mg/kg/d. Ang II infusion increased sBP in these mice, but there were no significant differences in sBP at day 8 ( Figure  1A ) and day 13 (data not shown) after Ang II infusion between these mice treated with adenovirus producing ␤-galactosidase (Ad-␤gal) or Ad-Adipo. HW/BW ratio was higher in Ad-␤gal-treated Adipo-KO mice than in Ad-␤gal-treated WT mice ( Figure 1B, lane 1 versus 3) . Adiponectin supplementation significantly protected against the increase in HW/BW ratio in Adipo-KO mice ( Figure 1B , lane 3 versus 4). However, Ad-Adipo-mediated adiponectin overproduction had no effect on HW/BW ratio in PPAR-␣-KO mice ( Figure 1B , lane 5 versus 6).
In WT mice, Ad-Adipo treatment ameliorated histological changes compared with Ad-␤gal treatment ( Figure 1C , top panels). Supplementation of adiponectin to Adipo-KO mice obviously resulted in histological improvement ( Figure 1C , middle panels), whereas adiponectin treatment did not produce histological changes in PPAR-␣-KO mice ( Figure 1C , bottom panels). Examination of tissues prepared by staining with van Gieson modified method showed improvement of cardiac fibrosis with adenoviral overproduction of adiponectin in both WT and Adipo-KO mice ( Figure 1D , top and middle panels), but not in PPAR-␣-KO mice ( Figure 1D , bottom panels). Interstitial fibrosis was more severe in both Ad-␤gal-treated Adipo-KO and PPAR-␣-KO mice compared with Ad-␤gal-treated WT mice ( Figure 1E , lane 1 versus 3 and 5). In WT mice, the adiponectin administration tended to reduce the severity of fibrosis compared to Ad-␤gal group (Pϭ0.0836, Figure 1E , lane 1 versus 2). In Adipo-KO mice, adiponectin supplementation markedly reduced cardiac fibrosis ( Figure 1E , lane 3 versus 4), whereas such treatment had no antifibrosis effect in PPAR-␣-KO mice ( Figure 1E , lane 5 versus 6).
Accumulation of Adiponectin in Ang II-Infused Heart Tissue
We observed the successful elevation of plasma adiponectin levels in mice treated with Ad-Adipo (supplemental Figure  III) . To investigate whether adiponectin directly acts on cardiac tissues, we performed immunohistochemistry by staining heart sections with antiadiponectin antibody. When WT, Adipo-KO, and PPAR-␣-KO mice were not treated with Ang II, no obvious expression of adiponectin was observed in these mice ( Figure 2A , left panels). Interestingly, accumulation of adiponectin protein was noted in Ang II-infused heart tissues of WT and PPAR-␣-KO mice, but not in Adipo-KO mice ( Figure 2A , middle panels). Ad-Adipo-mediated plasma adiponectin overexpression resulted in obvious accumulation of adiponectin protein even in heart tissues of 
Adiponectin Alters the Expression of Various Genes and ROS in Cardiac Tissues Under Ang II Infusion
In WT mice, adiponectin overexpression significantly reduced Collagen I and III mRNA levels ( Figure 3A and 3B, lane 1 versus 2). Supplementation of adiponectin did not change the levels of NADPH oxidase subunits ( Figure 3E and 3F, lane 1 versus 2), such as p22 phox and p47 phox , but significantly increased catalase and Cu,Zn-SOD mRNA levels ( Figure 3G and 3H, lane 1 versus 2). Adiponectin overexpression tended to increase PPAR-␣ mRNA levels ( Figure 3I , lane 1 versus 2) and significantly increased carnitine palmitoyltransferase 1b (CPT1b) mRNA levels known to be one of PPAR-␣ target genes (supplemental Figure V, lane 1 versus 2) . In Adipo-KO mice, adiponectin supplementation markedly reduced Ang II-induced increase in Collagen I and III, and TGF-␤1 ( Figure 3A to 3C, lane 3 versus 4). The elevated mRNA levels of NADPH oxidase subunits were also improved after adiponectin treatment ( Figure  3E and 3F, lane 3 versus 4) . Interestingly, adiponectin treatment enhanced catalase and Cu,Zn-SOD mRNA levels and rescued 
Adiponectin Activates PPAR-␣ in Cardiac Fibroblasts
Cardiac fibroblasts play a critical role in the pathogenesis of cardiac fibrosis. To understand further role of adiponectin-PPAR-␣ axis in cardiac fibrosis, we conducted in vitro experiments by using neonatal rat cardiac fibroblasts. 
Activation of AMPK Inhibits Ang II-Mediated Phosphorylation of ERK1/2 in Cardiac Fibroblasts
To understand how AMPK activation modulates Ang IImediated ERK1/2 signaling, we performed Western blotting. First, adiponectin enhanced phosphorylation of AMPK in a dose-dependent manner ( Figure 4B ). Second, Ang II phos- phorylated ERK1/2 but suppressed phosphorylation of AMPK ( Figure 4C, lane 1 versus 2) . Furthermore, adiponectin rescued the Ang II-induced reduction of AMPK phosphorylation and partially suppressed ERK1/2 activity under Ang II ( Figure 4C, lane 2 versus 3) . Third, we measured phosphorylation of AMPK and ERK1/2 by using AICAR to clarify the interaction between AMPK and ERK1/2 under Ang II. As expected, AICAR treatment phosphorylated AMPK ( Figure 4D, lane 1 versus 2 ) and the addition of Compound C reduced such phosphorylation ( Figure 4D, lane  2 versus 3) . Surprisingly, blockade of Ang II-induced ERK1/2 activity by PD98059 resulted in AMPK activation ( Figure 4E, lane 1 versus 2) . AICAR-induced AMPK activation partially suppressed Ang II-induced ERK1/2 phosphorylation ( Figure 4E, lane 1 versus 3) .
Discussion
The major findings of the present study were: (1) Ang II induced severe cardiac fibrosis in adiponectin-deficient mice. A striking finding of the present study was that treatment of Ang II-infused PPAR-␣-KO mice with adiponectin failed to improve cardiac fibrosis, ameliorate the expression levels of ROS-associated genes, and improve LV contraction. As shown in supplemental Figure V , adiponectin might exhibit its potency partly through PPAR-␣ activation in vivo. In consistent with our results, Yamauchi et al have demonstrated that fatty acid oxidation was enhanced in skeletal muscle of adiponectin transgenic mice, suggesting adiponectin-PPAR-␣ pathway. 15 However, we cannot conclude that adiponectin shows antioxidative and antifibrotic effects only through PPAR-␣-dependent pathway, because genetic PPAR-␣ deficiency has been shown to be quite proinflammatory. 16 Importantly, PPAR-␣ has been reported to correlate with ROS in several tissues. 17 Activation of PPAR-␣ inhibited Ang II-induced activation of NADPH oxidase and suppressed ROS production in human endothelial cells. 18, 19 Furthermore, a PPAR-responsive element (PPRE) has been identified in promoter regions of catalase and Cu,Zn-SOD genes, which are key enzymes that reduce ROS production. 20, 21 Taken together, PPAR-␣ activation seems to decrease tissue fibrosis, partly through ROS reduction. Some kinds of fatty acids are shown to enhance PPARs activity. 22, 23 Treatment with fatty acids reduced Ang II-induced elevation of collagen expression in cardiac fibroblasts (data not shown). For in vivo experiments, energy source in heart tissues switched fatty acids to glucose when myocardial tissues are overloaded (eg, pressure overloading, ischemia, etc.). There is a possibility that such metabolic switch may reduce PPAR-␣ activity and enhance cardiac remodeling. It would be worth testing in the future whether the administration of fatty acids improves Ang II cardiac fibrosis in Adipo-KO mice.
The present results support the recent experiments indicating that adiponectin suppressed superoxide production in heart tissue of ischemia-reperfusion model animals and that urinary levels of 8-OHdG were reduced in adiponectin transgenic mice. 24, 25 However, adiponectin deficiency caused no significant differences in catalase and Cu,Zn-SOD mRNA levels between WT and Adipo-KO mice, whereas superphysiological elevation of plasma adiponectin (4-to 5-fold increase) enhanced catalase and Cu,Zn-SOD mRNA levels both in WT and Adipo-KO mice (Figure 3 ). This result indicated that expression levels of these antioxidant enzymes were not determined only by adiponectin deficiency and suggested a possibility that some kind of compensatory mechanism occurs by adiponectin deficiency. Further investigations might clarify such discrepancy in the future. On the other hand, the activity of PPAR-␣ was increased by adiponectin within a physiological concentration in cardiac fibroblasts (Figure 4) . Thus, the in vivo potency of adiponectin is not always at the same level as in vitro.
Ang II does not only augment ROS formation and increase oxidase activity, but it also upregulates the mRNA and protein expression levels of the majority of NADPH oxidase subunits. 5, 6 In the present study, Ang II dose-dependently decreased PPAR-␣ mRNA levels (supplemental Figure II) , but it was uncertain whether cardiac PPAR-␣ activity was reduced in these mice. Tham et al demonstrated that PPAR-␣ and ␥ was downregulated in aorta of Ang II-administered apolipoprotein E-deficient mice and suggested that Ang II-induced NF-kappaB activation reduced PPAR-␣ and ␥ expressions. 26 Furthermore, Suzawa et al showed that NFkappaB activation resulted in the reduction of PPAR␥ activity by the association of NF-kappaB and PPAR␥, 27 and thus there is a possibility that similar effects may be observed in PPAR-␣ activity. Collectively, Ang II may reduce PPAR-␣ activity via NF-kappaB activation.
Degree of fibrosis was severe in Adipo-KO mice compared to WT mice treated with Ang II at 1.2 mg/kg/d, but no apparent differences were observed in fibrosis under Ang II infusion at 0.3 mg/kg/d (supplemental Figure I-d and I-e) . Systemic Ang II infusion elevates blood pressure, causes mechanical stress in cardiac myocytes, and activates various signaling molecules. There is a possibility that we observed no significant differences between WT and Adipo-KO mice treated with Ang II at 0.3 mg/kg/d because these stressinduced signals may complicatedly crosstalk with adiponectin signaling and Ang II receptor signaling each other.
AMPK is considered a key player in the pathogenesis of cardiac hypertrophy, although its mechanism remains elusive. In mouse heart, AMPK is activated during pressure overloadinduced hypertrophy. 28 Previous reports showed a lower AMPK activation in myocardium of Adipo-KO mice after transverse aortic constriction (TAC) operation, indicating that the lack of stimulatory effect of adiponectin on AMPK accounted for severe TAC-induced cardiac hypertrophy observed in Adipo-KO mice. 29, 30 In addition, we herein demonstrated that the adiponectin-AMPK-PPAR-␣ pathway might involve in one of pathogenesis for cardiac fibrosis. Consistent with our results, activated AMPK was recently reported to undergo translocation from cytoplasm to nucleus and thus induces the transcription of PPAR-␣ in C2C12 myocytes. 31 Supplemental Figure VIII indicates that AMPK activation avoids Ang II-induced reduction of PPAR-␣ activity. Furthermore, Figure 4E suggests that AMPK and ERK1/2 control each other in Ang II-treated cardiac fibroblasts. However, there is a study limitation in present in vitro experiments. The active derivative of AICAR, ZMP, modulates other AMP-sensitive enzymes, such as glycogen phosphorylase and fructose-1,6-bisphosphatase. 32 In addition, AICAR can compete with released adenosine for reuptake into cells. Compound C is also considered as an AMPK inhibitor, but its selectivity for AMPK remains uncertain. There is the necessity to confirm the present results by using expression vectors for AMPK and DN-AMPK or siRNA for AMPK in the future.
Another important finding of the present study was the accumulation of adiponectin in the myocardium (Figure 2A ). In the Ad-␤gal group, myocardial sections of Ang II-treated WT and PPAR-␣-KO mice were stained with antiadiponectin antibody whereas no such staining was observed in those of Adipo-KO mice. We examined adiponectin mRNA level in heart tissue, but we could not detect adiponectin mRNA expression even in Ad-Adipo group (data not shown). These results suggest that circulating adiponectin accumulated in the injured heart tissues. We also measured cardiac mRNA levels of adiponectin receptors, such as AdipoR1, AdipoR2, and T-cadherin, but no apparent differences of these mRNA levels were observed in WT and Adipo-KO mice (data not shown). Previous studies used the solid-phase binding assay and showed that adiponectin binds specifically to Collagen types I, III, and V. 33 The results depicted in supplemental Figure II indicate that Ang II enhances the expression of Collagen I and III in heart tissue. Together, these observations support the hypothesis that circulating adiponectin can potentially accumulate or bind to the injured matrix that abundantly express collagen, but the precise mechanism for adiponectin accumulation in the injured heart tissue remains to be elucidated.
In summary, we herein demonstrated in the present study that adiponectin, Ang II, and PPAR-␣ are closely associated with each other and partly contribute to the pathogenesis of cardiac fibrosis and heart failure, but the precise mechanism has not been fully clarified. Adiponectin enhances PPAR-␣ activity through AMPK, whereas Ang II reduces its activity via ERK1/2. Moreover, AMPK and ERK1/2 control each other in Ang II-treated cardiac fibroblasts. PPAR-␣ activation might result in ROS reduction, and finally protection against cardiac fibrosis and heart failure. In conclusion, adiponectin protects against cardiac fibrosis and dysfunction at least partly through AMPK-dependent PPAR-␣ activation pathway. The present study may provide novel and useful therapeutic strategies against organ fibrosis.
